Dapagliflozin attenuates residual cardiac remodeling after surgical ventricular reconstruction in mice with an enlarged heart after myocardial infarction

Ma, Siyuan; Chen, Lu; Yan, Junyu; Shen, Mengjia; Zhang, Rui; Li, Mingjue; He, Mingyuan; Chen, Kaitong; Zhu, Yingqi; Lin, Hairuo; Wang, Yuegang; Liao, Wangjun; Bin, Jianping; Zheng, Cankun; Liao, Yulin

doi:10.1016/j.biopha.2022.113765

Cited by 6 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These clinical beneficial effects of dapagliflozin rely on several pathophysiologica mechanisms that have been investigated in different experimental and clinical studies Thus, experimental studies have shown in different animal models with HF that dapagli flozin inhibits ventricular remodeling, attenuates cardiometabolic dysregulation and dia betes-induced diastolic dysfunction, reduces cardiac fibrosis and inflammation, improve These clinical beneficial effects of dapagliflozin rely on several pathophysiological mechanisms that have been investigated in different experimental and clinical studies. Thus, experimental studies have shown in different animal models with HF that dapagliflozin inhibits ventricular remodeling, attenuates cardiometabolic dysregulation and diabetesinduced diastolic dysfunction, reduces cardiac fibrosis and inflammation, improves aorta sympathetic tone and endothelial dysfunction [109][110][111][112][113][114][115][116][117][118]. The impact of dapagliflozin on cardiac remodeling has been confirmed in patients with chronic HF in the DAPA-MODA study, with significant improvements in left atrial volume, left ventricular geometry parameters and natriuretic peptides levels, after only 6 months of treatment [119].…”

Section: Discussionmentioning

confidence: 86%

Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin

Escobar,

Pascual-Figal,

Manzano

et al. 2023

JCM

View full text Add to dashboard Cite

Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in managing patients with HF, regardless of ejection fraction, to reduce HF burden. The DAPA-HF and DELIVER trials, and particularly, the pooled analysis of both studies, have shown that dapagliflozin significantly reduces the risk of cardiovascular death, all-cause death, total HF hospitalizations, and MACE in the whole spectrum of HF, with sustained benefits over time. Recent data have shown that the full implementation of dapagliflozin in clinical practice would translate into a robust reduction in hospitalizations for HF and death in real-life populations. Many pathophysiological mechanisms have been involved in these benefits, particularly the positive effects of dapagliflozin on reversing cardiac (atrial and ventricular) remodeling, reducing cardiac fibrosis and inflammation, and improving endothelial dysfunction. In this manuscript, we reviewed from a practical point of view the role of dapagliflozin in the management of the whole spectrum of patients with HF.

show abstract

Section: Discussionmentioning

confidence: 86%

Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin

Escobar,

Pascual-Figal,

Manzano

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…A recent study from October 2022 examined the effect of administration of the SGLT2 inhibitor, dapagliflozin, in mice with a large LVA. 11 The study found that dapagliflozin alone did not have a significant positive effect on remodeling. However, in mice that had undergone surgical reconstruction, remodeling was improved.…”

Section: Discussionmentioning

confidence: 94%

Left Ventricular Reconstruction after Dor—Sailing Close to the Wind?

Großmann,

Krasivskyi,

Djordjevic

et al. 2024

Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Postinfarction left ventricular aneurysm (LVA) still remains a complication after myocardial infarction with a poor prognosis. Its incidence has decreased due to improved treatment, however, it may have experienced a renaissance due to the coronavirus disease 2019 pandemic. In this retrospective, single-center cohort study, we analyzed n = 17 patients who underwent left ventricular reconstruction after Dor. The results show a mean intensive care unit stay of 8 ± 16 days and a 30-day mortality rate of 6%. Mean postoperative ejection fraction was 44 ± 8% indicating an increase in all but three cases. This suggests that patients with an LVA can be successfully treated, and it is safe when performed by experienced surgeons. Therefore, they should still be considered for surgery early on.

show abstract